Laboratory Fraud Penalties: What the Numbers Actually Mean

Laboratory fraud penalties can include three times the government’s loss, a civil penalty for each false claim and exclusion from federal healthcare programs. A requisition that automatically adds unnecessary tests can repeat the same billing problem across a laboratory’s business. For someone who knows the order forms, the referral payments or the billing system, the claim count shows how far that instruction reached.

What Are the Penalties for Laboratory Fraud?

The False Claims Act combines damages based on the government’s loss with a separate penalty for each false claim. The Justice Department’s July 3, 2025 adjustment set that penalty range at $14,308 to $28,619 per claim.

The claim count supplies another part of the bill. A repeated order-form instruction can therefore matter as much as the price of an individual test: it may generate claim after claim for testing the patient never needed.

The Order Form Can Multiply the Claims

An independent laboratory generally performs and bills for tests that someone else orders. The ordering clinician holds the medical record explaining why the patient needs the test. The laboratory holds the information sent with the order and the claim built from it. That separation puts the requisition, the clinical decision and the billing record at the center of laboratory fraud.

Physicians Toxicology Laboratory agreed to pay $4,425,000 in January 2025 to resolve allegations involving unnecessary urine drug and hormone testing. According to the government’s account of the settlement, the laboratory encouraged practices to use forms ordering presumptive and definitive urine drug testing together: an initial screen and a more detailed test. Its in-office urine collectors typically filled out the blanket orders.

The government also alleged that the lab billed separately for hormone tests used to check specimen validity, even though Medicare’s drug-testing payment already covered that work. The alleged problems were built into how the orders were prepared and how the services were billed. Taxpayers paid for testing that the government said patients did not need.

This concern predates modern genetic-testing campaigns. Model Plan Helps Laboratories Fight Fraud, published in Laboratory Medicine in 1997, described reviewing standing orders and tracking tests by billing code. It also described requisitions that let physicians document the medical necessity of each test. The article puts the paperwork where it belongs: alongside the decisions that generate the claim.

Referral Payments Can Reach the Claims They Buy

Laboratory kickbacks can turn a referral payment into a false-claims problem when the resulting tests are billed to Medicare. The Anti-Kickback Statute and physician self-referral law reach payments and financial relationships behind those orders, while the Eliminating Kickbacks in Recovery Act also reaches laboratory referrals involving private health plans.

For an insider considering a qui tam case, the useful connection is who gets paid, what the payment buys and which tests follow. A processing fee, rent payment or consulting contract can hide the price of a referral.

A whistleblower’s complaint against Health Diagnostic Laboratory described how a panel could remove the doctor’s choice about individual tests:

The complaint alleged that the panel included duplicative tests. The significance for a penalties inquiry is the repeated decision: a choice built into the panel follows the specimen through testing and into billing.

From Genetic-Testing Orders to Medicare Payments

LabSolutions turned genetic-testing orders into Medicare payments. A jury convicted its owner in a criminal trial. In its account of the trial evidence, the Justice Department described telemedicine doctors signing genetic-testing orders without evaluating medical necessity and often without speaking to the beneficiaries.

LabSolutions billed Medicare more than $463 million. Medicare paid more than $187 million, and the owner personally received more than $21 million.

A laboratory’s criminal case and corporate settlement can concern different defendants. In its guilty plea, Nichols Institute Diagnostics admitted misbranding test kits, while parent company Quest Diagnostics entered a non-prosecution agreement. The federal civil settlement was $262 million.

Laboratory Fraud Judgments Depend on How the Case Was Decided

Laboratory fraud judgments can follow a trial, an agreement or a defendant’s failure to defend the case.

What Happened to the Health Diagnostic Laboratory Scandal?

Health Diagnostic Laboratory’s corporate settlement and the later judgment against its former chief executive and two BlueWave marketers were separate outcomes. In April 2015, HDL agreed to pay $47 million to resolve allegations involving processing and handling fees paid for referrals and unnecessary testing.

The later civil trial concerned the people behind the arrangements. A jury found the former chief executive and two BlueWave marketers liable, and the court entered a judgment of $114,148,662 in May 2018. The court tripled damages, accounted for settlement credits and added $63.8 million in per-claim penalties.

Some lab False Claims Act settlements carry admissions about how the orders were built. Genotox Laboratories admitted offering custom profiles that preselected tests for all or nearly all of a provider’s patients, generally in the highest reimbursement categories. That admission describes the ordering mechanism directly.

Default Judgments After Defendants Failed to Defend

The government obtained $140 million in judgments against South Carolina pain clinics, drug-testing laboratories and a counseling center in the Oaktree case. The allegations concerned financial incentives for urine-test referrals and unnecessary testing. The defendants failed to defend the cases.

The laboratory network that included Luminus Diagnostics, Tennessee Valley Regional Laboratories and Tomoka Medical Lab likewise faced more than $370 million in default judgments. In the Premier Medical case, the government announced $114.5 million in judgments, with a default judgment against Premier Medical. The court treated the allegations against that company as true because of its default.

Agreed Judgments and Admissions

In the Oaktree case, the chiropractor who owned Labsource separately agreed to a $9 million civil consent judgment. In his accompanying guilty plea, he admitted providing kickbacks through a direct-bill program that let referring providers earn revenue from their own laboratory referrals.

BestCare Laboratory Services and its owner reached an agreement to resolve a judgment over inflated mileage-based laboratory technician travel fees.

Exclusion and Oversight Reach Beyond the Payment

Exclusion concerns participation in federal health care programs. An agreement can also require a laboratory to change how it reviews orders, claims and referral relationships.

RenRX accepted a 25-year exclusion as part of the UTC Laboratories civil resolution.

Employing an excluded person can itself produce a civil monetary penalty settlement. Laboratory Corporation of America agreed to pay $45,466 after self-disclosing conduct at a Florida laboratory. HHS-OIG alleged that LabCorp employed someone it knew or should have known was excluded from federal health care programs.

The Physicians Toxicology Laboratory settlement also required an integrity agreement. It called for a clinical director to review clinical decision-making policies and statements in marketing materials or by sales staff. An independent reviewer would examine whether claims reflected medically necessary, appropriately documented services. Those controls reach the people making the sales pitch and preparing the order, where the alleged problem began.

The Insider’s View Connects the Test to the Money

Urine collectors see who fills out the blanket orders. Laboratory staff see which tests run on the specimens, and billing staff see which services become separate claims. Sales staff see the referral arrangements that bring the work in. Comparing the requisition, the testing record, the claim and the payment can connect those decisions.

That is the connection we examine with you: the particular tests, the instructions that repeated them and the people who understood how the billing worked. The cases above began with conduct inside a business, long before a settlement or judgment supplied the headline.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know How Those Claims Were Made

If you know who built the blanket orders, approved the referral payments or directed the billing, talk to our whistleblower experts about what happened inside your laboratory. We build the case with you and bring in laboratory fraud whistleblower lawyers who understand test ordering, medical necessity and the money behind referrals. We stay beside you through the case, putting your knowledge of the business to work against the people who made those decisions.